Company Overview
- Headquarters
- 4955 Directors Place, San Diego, CA 921219380 Judicial Drive, San Diego, CA 92121
- Website
- sorrentotherapeutics.com
- Phone
- (800) 952-5210(858) 203-4100
- Employees
- 233
- Founded in
- 2009
- Industry
- BioTech/Drugs
- Stock Symbol
- NASDAQ:SRN
- NAICS Codes
-
32 - Manufacturing325 - Chemical Manufacturing3254 - Pharmaceutical and Medicine Manufacturing32541 - Pharmaceutical and Medicine Manufacturing54 - Professional, Scientific, and Technical Services541 - Professional, Scientific, and Technical Services
- SIC Codes
-
28 - Chemicals and Allied Products283 - Drugs
Financials & Stats
Revenue
$57B
Total Funding Amount
$685M
Recent News & Media
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
- Mar 27, 2025
- news.bloomberglaw.com
Scilex Holding Company Announces that the U.S. Bankruptcy
- Jan 31, 2025
- globenewswire.com
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
- Oct 29, 2024
- biospace.com
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025
- Sep 26, 2024
- stocktitan.net
Sorrento Therapeutics Restructuring Chief Hosted Party for Judges Who Later Oversaw Its Liquidation
- Sep 3, 2024
- wsj.com
Who are the leading innovators in transdermal drug delivery for the pharmaceutical industry?
- Aug 29, 2024
- pharmaceutical-technology.com
Who is Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in San Diego, California. The company employs 233 individuals and has generated $57 million in revenue. Sorrento Therapeutics focuses on developing innovative therapies for a wide range of diseases, including cancer, autoimmune disorders, inflammatory conditions, viral infections, and neurodegenerative diseases. Their therapeutic approach utilizes a proprietary G-MAB™ library and targeted delivery modalities, encompassing chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), and bispecific antibody approaches. Additionally, the company is developing pain management solutions, such as resiniferatoxin (RTX) and SEMDEXA™. In response to the COVID-19 pandemic, Sorrento Therapeutics has dedicated resources to developing antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, alongside diagnostic test solutions like COVISTIX™ and COVITRACK™. To learn more about Sorrento Therapeutics and their innovative therapies, visit their website at sorrentotherapeutics.com.
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The company operates websites and provides various services. Sorrento Therapeutics, Inc. is headquartered in San Diego, California. The company is subject to various legal and privacy regulations. Sorrento Therapeutics, Inc. has two listed addresses in San Diego, California: 4955 Directors Place and 9380 Judicial Drive. The company's contact information includes a phone number, 8009525210, and email addresses for privacy inquiries ([email protected]) and legal matters ([email protected]). Sorrento Therapeutics, Inc. operates within the healthcare, biotechnology, and pharmaceuticals industries. The company's activities are subject to legal and privacy regulations.